-$0.53 Earnings Per Share Expected for Scpharmaceuticals Inc (SCPH) This Quarter

Brokerages forecast that Scpharmaceuticals Inc (NASDAQ:SCPH) will post earnings per share of ($0.53) for the current quarter, according to Zacks. Zero analysts have issued estimates for Scpharmaceuticals’ earnings. The highest EPS estimate is ($0.49) and the lowest is ($0.56). The company is expected to report its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Scpharmaceuticals will report full year earnings of ($2.12) per share for the current financial year, with EPS estimates ranging from ($2.23) to ($2.01). For the next fiscal year, analysts expect that the firm will post earnings of ($2.75) per share, with EPS estimates ranging from ($2.90) to ($2.60). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that follow Scpharmaceuticals.

A number of analysts recently issued reports on the company. Zacks Investment Research cut Scpharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday. Jefferies Group began coverage on Scpharmaceuticals in a research report on Tuesday, December 12th. They set a “buy” rating and a $23.00 price objective for the company. Leerink Swann began coverage on Scpharmaceuticals in a research report on Tuesday, December 12th. They set an “outperform” rating and a $20.00 price objective for the company. Finally, BMO Capital Markets began coverage on Scpharmaceuticals in a research report on Tuesday, December 12th. They set an “outperform” rating and a $24.00 price objective for the company.

In related news, major shareholder 5Am Partners Iv, Llc acquired 654,762 shares of the firm’s stock in a transaction on Tuesday, November 21st. The stock was bought at an average cost of $14.00 per share, with a total value of $9,166,668.00. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.

A number of institutional investors have recently bought and sold shares of SCPH. AWM Investment Company Inc. acquired a new stake in Scpharmaceuticals during the 4th quarter worth approximately $1,996,000. Nicholas Investment Partners LP acquired a new stake in Scpharmaceuticals during the 4th quarter worth approximately $1,500,000. Bank of New York Mellon Corp acquired a new stake in Scpharmaceuticals during the 4th quarter worth approximately $414,000. Finally, Monashee Investment Management LLC acquired a new stake in Scpharmaceuticals during the 4th quarter worth approximately $230,000. 0.07% of the stock is owned by institutional investors.

Shares of Scpharmaceuticals (SCPH) traded up $0.32 during midday trading on Wednesday, hitting $12.46. The company had a trading volume of 12,000 shares, compared to its average volume of 27,751. Scpharmaceuticals has a 1 year low of $11.50 and a 1 year high of $18.17.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.themarketsdaily.com/2018/02/14/0-53-earnings-per-share-expected-for-scpharmaceuticals-inc-scph-this-quarter.html.

Scpharmaceuticals Company Profile

scPharmaceuticals, Inc, is a biopharmaceutical company. The Company is engaged in developing pharmaceutical products for subcutaneous delivery. The Company offers sc2Wear Infusor, which is a small pump that attaches to the body using a standard medical adhesive. The sc2Wear Infusor injects the drug into the body slowly, similar to an intravenous (IV) drip.

Get a free copy of the Zacks research report on Scpharmaceuticals (SCPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply